Background L-dopa is an important antiparkinsonian drug. It is a precursor of dopamine and the other catecholamines. Potentially, administration of L-dopa could lead to increased urinary excretion of catecholamines and their metabolites to abnormal amounts. The current study aimed to determine these excretions in patients with Parkinson's disease (PD) receiving L-dopa compared with suitable controls. This is the first assessment of the effect of exogenous administration of L-dopa on urinary free metadrenalines.
Introduction
Parkinson's disease belongs to a group of motor system disorders whose primary symptoms include tremor, rigidity, slowness of movement and impaired balance or coordination. This progressive illness is due to the relatively selective degeneration of dopamine-producing brain cells. The mainstay of treatment is oral dopaminomimetic therapy often given in the form of the dopamine precursor L-dopa (3,4 dihydroxyphenylalanine) in an attempt to overcome the e¡ects of reduced dopamine in the brain. 1 Unlike dopamine itself, this substance is able to cross the blood-brain barrier where it is converted to dopamine. 1 There are, potentially, three pathways for the peripheral metabolism of exogenously-administered L-dopa, thereby limiting its availability to reach the brain. These are decarboxylation to dopamine, O-methylation to 3-methoxytyrosine and transamination to 3,4 dihydroxyphenyl pyruvic acid ( Figure 1 ). 2, 3 Therapeutic manoeuvres have been aimed at inhibition of peripheral decarboxylation (e.g. by carbidopa or benserazide) and of O-methylation (e.g. by entacapone) in order to increase availability and decrease dose thereby reducing the side e¡ects associated with higher doses of L-dopa. 2, 3 However, excess dopamine formed in the circulation from exogenously-administered L-dopa may then, in turn, be converted by peripheral tissues to the other catecholamines: noradrenaline, adrenaline, or their metabolites 2,4 (for recent reviews of dopamine metabolism see Goldstein et al., 2003 5 and Eisenhofer et al., 2004 6 ) . A simpli¢ed scheme illustrating the formation of analytes most often measured in the investigation of phaeochromocytoma is shown in Figure 2 . If L-dopa administration leads to urinary excretion of these substances in higher than normal amounts, this could result in diagnostic confusion and misidenti¢cation of the ¢ndings as indicating the presence of tumour during routine investigation. 7, 8 The purpose of the present study was to determine the urinary excretion of catecholamines and their metabolites in patients with Parkinson's disease who were receiving L-dopa compared with suitable controls.
Patients and methods
Three groups of patients were examined. The ¢rst control group comprised 50 adults (36 females,14 males) of mean age 50 (range 19--76) years, randomly selected from request form information, who were being investigated for the presence of phaeochromocytoma but were subsequently found not to have the disease. None of these patients had Parkinson's disease (PD). The 24-h urine excretion of vanillylmandelic acid (VMA), 5-hydroxyindoleacetic acid (HIAA), homovanillic acid (HVA), noradrenaline (NA), adrenaline (AD) dopamine (DA), free normetadrenaline (fNMA) and free metadrenaline (fMA) were within their respective reference ranges. 9--11 Results for these analytes from this group were recalculated as mmol per mole creatinine.
The second control group consisted of 20 patients (9 females, 11 males) of mean age 58 (range 46--80) years. Each had a diagnosis of PD but were not currently receiving L-dopa therapy. The third group comprised 39 patients (12 females, 27 males) of mean age 63 (range 47--78) years, also with PD, but receiving L-dopa therapy at an average daily dose of 500 (range 200--1290) mg.
Random urine specimens (20 ml) were obtained from the second and third groups of patients during their routine movement disorders clinic visits. Shortly after collection each urine specimen was stabilised by the addition of a drop of hydrochloric acid then sent to the biochemistry laboratory for analysis. On receipt, each specimen was checked for adequate acidity (pHo4) and analysed for VMA, HIAA, HVA, NA, AD, DA, fNMA, fMA, creatinine and paracetamol by methods and equipment described previously. 11, 12 Analytes were expressed as the analyte/creatinine ratio (mmol/ mol creatinine).
The normality of distribution for each analyte/creatinine ratio in each of the three patient groups was assessed by the Kolmogorov-Smirnov test. Statistical analysis of di¡erences between the three groups was performed by one-way analysis of variance for each analyte. Where signi¢cant di¡erences were detected (Po0.05) pairwise comparison of group means was performed by the Student-Newman-Keuls test. Analysis of variance was also performed by the non-parametric Kruskal-Wallis technique. In addition, for all patients with PD (groups 2 and 3), the relationship between the analyte/creatinine ratio and the daily dose of L-dopa was assessed by Spearman rank correlation. Calculations were performed using the MedCalct version 7.2 statistical software package (Mariakerke, Belgium).
Results
All 50 patient samples in group 1 without PD were negative for paracetamol. In the 59 patients in groups 2 and 3 with PD, antiparkinson drug therapy included the dopamine agonists ropinirole (22 patients), pramipexole (16 patients), pergolide (6 patients) and cabergoline (3 patients). Other antiparkinson drugs were selegiline (17 patients), domperidone (6 patients), amantadine (6 patients), entacapone (1 patient) and orphenadrine (1 patient). In addition to other drugs, 11 patients were also receiving antidepressants, hypnotics or anxiolytics. Biochemical analysis 12 indicated that 29 of the 59 patients with PD were positive for paracetamol. This had the e¡ect of variously limiting the availability of some analytical results due to in-vitro interference, particularly for AD, fNMA and fMA. 12 Kolmogorov-Smirnov test showed that results met the criteria for normal distribution in all groups excepting only those of AD in group 1 patients (P ¼ 0.013) and fNMA in group 3 patients (P ¼ 0.022). Results of oneway analysis of variance amongst the 3 patient groups are summarised in Table 1 . These showed that there was no signi¢cant di¡erence between the three groups forVMA, HIAA or NA. Urine DA and its metabolite HVA were, on average, much higher in group 3 patients (PD receiving L-dopa) than those of either group 1 (controls) or group 2 (control PD patients not receiving L-dopa). Respective mean values for DA and HVA in group 3 patients were at least 20-fold and 10-fold higher than those in the control groups. Furthermore, mean urine fNMA and fMA results were also found to be 2fold to 3-fold higher in PD patients receiving L-dopa than for the control groups. Results for AD were marginally higher in group 2 patients (PD not receiving Ldopa) for reasons which are unclear. Very similar ¢ndings were obtained following subsequent analysis of variance by the non-parametric Kruskal-Wallis test. The relationships between each analyte/creatinine ratio and the daily dose of L-dopa in the PD patients in groups 2 and 3, as examined by Spearman rank correlation, are summarised in Table 2 . There was no correlation for urinary VMA, HIAA, NA or AD results with administered daily dose of L-dopa. However, DA and its metabolite HVA were correlated with L-dopa dose. In addition, urinary fNMA and fMA also showed a correlation with daily L-dopa intake.
Discussion
Not surprisingly, urine DA excretion, and that of its major metabolite, HVA, were found to be signi¢cantly higher in patients treated with L-dopa than either: (1) controls without PD, or (2) patients with PD but not receiving L-dopa. In addition, both DA and HVA exhibited a signi¢cant positive correlation with daily dose of L-dopa. Such increases in HVA or DA excretion in response to L-dopa administration have been noted previously. 13--16 Reassuringly, despite its position as a precursor of catecholamine synthesis, L-dopa administration in the amounts described in the present study did not result in abnormally elevated excretion of VMA, HIAA, NA or AD. Furthermore, their excretions did not exhibit a correlation with the daily dose of L-dopa. Hence, these analytes are likely to retain their value as tests for indicating the presence of chroma⁄n or carcinoid tumours in patients receiving L-dopa ther-apy at the doses described in this study. Interestingly, in PD patients not receiving L-dopa, urine AD did exhibit a marginally higher excretion, on average, than either the control subjects without PD or those with PD who were receiving L-dopa. It has been reported that urinary VMA is increased following treatment with L-dopa at high dose (1.5--7.5 g daily), or at much lower dose (800--1000 mg daily) combined with a dopa decarboxylase inhibitor (benserazide). 17 However, in that study, VMA was measured spectrophotometrically by the method of Pisano et al. 18 In a similar, though more recent study, where PD patients were treated with an average daily dose of L-dopa of 950 mg in combination with carbidopa, urinary VMA, measured by high performance liquid chromatography with electrochemical detection as in the present study, was not signi¢cantly di¡erent from untreated controls. 19 Thus, previously reported high values for urinary VMA following L-dopa administration could be explained by the limited speci¢city of earlier analytical techniques.
By contrast, urine metadrenalines, whether measured spectrophotometrically by the Pisano technique, 20 or by gas chromatography 21 are reported to be not increased following L-dopa administration. 17, 19 Both these studies assessed changes in urinary excretion of total (conjugated þ free) metadrenalines. However, the present study examined the e¡ects of L-dopa therapy on only the urinary free fractions. The urinary free metadrenalines are a potentially useful test in the detection of phaeochromocytoma particularly in those positive cases when excretion of the native catecholamines is normal. 11 Preliminary ¢ndings from a tertiary care centre showed that urinary fNMA and fMA are more sensitive tests than either plasma or urine catecholamines or urinary VMA. 22 However, in the present study, both urine fNMA and fMA showed signi¢cantly higher values in PD patients receiving L-dopa than for either of the control groups. Urine fNMA and fMA were also positively correlated with L-dopa daily dose indicating a direct e¡ect of the drug on their urinary excretion. Therefore, L-dopa therapy may result in production of false positives and thereby decreases the diagnostic value of fNMA and fMA measurement as indicators of the presence of phaeochromocytoma and related tumours.
